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BACKGROUND: Cyclooxygenase-2 (COX-2) is selectively over-expressed in colorectal tumours. The mechanism of COX-2 induction
in these tumours is not fully understood, although evidence suggests a possible link between nuclear factor (NF)-kB and COX-2. We
hypothesised an association between COX-2 expression and NF-kB-p65, NF-kB-p50 and IkB-kinase-a (IKKa) in both epithelial and
stromal cells in human colorectal cancer.
METHODS: Using immunohistochemistry, we measured COX-2, NF-kB-p65, NF-kB-p65 nuclear localisation sequence (NLS), NF-kB-
p50, NF-kB-p50 NLS and IKKa protein expression in matched colorectal biopsy samples comprising both non-tumour and adjacent
tumour tissue from 32 patients with colorectal cancer.
RESULTS: We have shown that stromal cells of malignant and surrounding normal colorectal tissue express COX-2. In all cell types of
malignant tissue, and in vascular endothelial cells (VECs) of neighbouring normal tissue, COX-2 expression was strongly associated
with NF-kB-p65 expression (Pearson’s correlation, P¼0.019 for macrophages, P¼0.001 for VECs, P¼0.002 for fibroblasts
(malignant tissue), and P¼0.011 for VECs (non-malignant tissue)) but not NF-kB-p50 or IKKa.
CONCLUSIONS: These data suggest that in these cells COX-2 induction may be mediated through activation of the canonical NF-kB
pathway. Finally, the lack of association between COX-2, NF-kB-p65 or IKKa in stromal cells with the clinical severity of colorectal
cancer as determined by Duke’s stage, suggests that COX-2, NF-kB-p65 and IKKa expression are possibly early post-initiation events,
which could be involved in tumour progression.
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Adenocarcinoma of the colon and rectum is the second leading
cause of death from cancer in the industrialised world (Midgley
and Kerr, 1999). The high prevalence of the disease is a driver for
understanding the underlying molecular mechanisms of colorectal
carcinogenesis.
Several epidemiological studies have reported a 40–50%
decrease in the relative risk of colorectal cancer in persons
chronically using non-steroidal anti-inflammatory drugs (NSAIDs)
(Thun et al, 1991; Marnett, 1992; Giovannucci et al, 1995),
indicating that these drugs may have a chemoprotective and
possibly chemotherapeutic effect. Data from human studies, have
shown that the NSAID, sulindac, can reduce the number and size
of polyps in patients with familial adenomatous polyposis (FAP)
(Waddell and Loughry, 1983; Giardiello et al, 1993).
Most NSAIDs in current use inhibit the action of cyclooxygenase
(COX), a key enzyme in the production of prostaglandins (PGs).
Cyclooxygenases are intracellular enzymes that catalyse the
conversion of arachidonic acid to PGs and related eicosanoids.
Isoforms of the COX-2 gene have been identified, which encode for
the constitutively expressed COX-1 and the inducible COX-2. In
the last decade, several studies have indicated a link between the
expression of COX-2 and the pathogenesis of several types of
human cancers, including breast (Brueggemeier et al, 1999; Half
et al, 2002), gastric (Ristima ¨ki et al, 1997), lung (Hida et al, 1998)
and colorectal adenocarcinomas (Eberhart et al 1994; Tomozawa
et al, 2000).
Although enhanced COX-2 expression in colorectal cancer
tissues has been widely observed, the mechanisms that regulate
the expression of COX-2 in colorectal tumours are not completely
understood. Cyclooxygenase-2 expression can be induced by a
variety of stumuli, including oncogenic viruses, growth factors,
tumour promoters and cytokines.
Sequence analysis of the 50-flanking region of the COX-2 gene
shows two nuclear factor-kB (NF-kB) sites (Tazawa et al, 1994).
In vitro inhibition of this protein has been shown to attenuate
COX-2 expression in colorectal cancer cells, indicating that NF-kB
may play an important role in COX-2 induction (Plummer et al,
1999; Williams et al, 2003). Earlier, we have shown that
upregulation of COX-2 is accompanied by increased expression
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sof NF-kB-p65 and IkB-kinase-alpha (IKKa) in human colorectal
cancer epithelial cells (Charalambous et al, 2003).
Recent studies have shown that tumour stroma also contributes to
enhanced COX-2 expression in colorectal cancer. Increased levels of
COX-2 have been localised in macrophages (Sheehan et al, 2003; Liu
et al, 2005), fibroblasts (Sonoshita et al, 2002; Adegboyega et al, 2004)
and vascular endothelial cells (VECs) (Brown and DuBois, 2005),
indicating that both host and tumour cells may contribute to the
production of PGs within the tumour microenvironment and the
subsequent development of cancer growth.
We have therefore studied tissue biopsies obtained from
patients with diagnosed primary colorectal carcinoma undergoing
surgical treatment for their disease, for differences in expression of
COX-2 in epithelial and stromal cells (macrophages, fibroblasts
and VECs), in malignant and adjacent normal colorectal tissue,
and for alterations in the expression of the upstream intracellular
proteins, which seem to be associated to COX-2 expression,
namely NF-kB-p65, NF-kB-p50 and IKKa.
MATERIALS AND METHODS
Patients
The study adhered to the tenets of the Declaration of Helsinki.
Surgical specimens of primary tumours were obtained with
informed consent from 32 patients (21 men and 11 women; aged
44–80 years, mean age 64.0 years±1.63 s.e.m.), with histologically
verified colorectal cancer, treated at the Department of Surgery,
York District Hospital, York, UK. Ethical approval for the study
was obtained from the Human Research Ethics Committee at York
District Hospital. A total of 17 patients had colon cancer and 15
had rectal cancer. Tumours were classified according to the Duke’s
classification (see Table 1). A total of 5 patients had Duke’s A,
12 had Duke’s B and 10 had Duke’s C. The entire study was carried
out blind using coded tissue sections.
Tissue specimens
Tissue samples taken at operation for histopathological
confirmation of disease were fixed in 4% buffered formal-
dehyde and embedded in paraffin wax; sections surplus
to pathology requirements were made available for the
study. For 23 patients, tissue sections of both normal
and malignant colon or rectum were provided, whereas
for nine patients only malignant tissue sections were
available.
Antibodies
The immunoglobulins (IgGs) used were as follows: (1) Goat
polyclonal anti-human COX-2 (Santa Cruz Biotechnology;
dilution 1:1500); (2) Rabbit polyclonal anti-human NF-kB-p65
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1:1000);
(3) Mouse monoclonal anti-human NF-kB-p65 nuclear localisation
sequence (NLS) (Chemicon Millipore, Watford, UK; dilution
1:100); (4) Mouse monoclonal anti-human IKKa (Santa Cruz
Biotechnology; dilution 1:800); (5) Goat polyclonal anti-human
NF-kB-p50 (Santa Cruz biotechnology; dilution 1:200); and (6)
Rabbit polyclonal anti-human NF-kB-p50 NLS (Santa Cruz
Biotechnology; dilution 1:100). All antisera were obtained from
Santa Cruz Biotechnology.
Immunohistochemistry
The expression of COX-2, NF-kB-p65, NF-kB-p65 NLS, NF-kB-p50,
NF-kB-p50 NLS and IKKa in epithelial and stromal cells (macro-
phages, fibroblasts and VECs) of normal and malignant colorectal
Table 1 Patient demographic information
Age
a Sex Tumour site Duke’s stage Drug history Tobacco use Alcohol
b
72 M Colon B None No 8+
68 M Colon C N/A No N/A
66 F Colon C1 5-Fluorouracil, Enalapril No 0
69 M Rectum C Co-codamol No 1–7
49 F Colon B N/A Yes N/A
63 F Rectum N/A N/A No N/A
52 M Rectum C1 Adalat No 1–7
75 M Colon C N/A No N/A
68 M Colon B Atenolol, Prednisolone, Warfarin, Diltiazem, Isosorbide, Gliclazide, Co-danthramer No 1–7
69 M Rectum C1 Atenolol No 8+
70 F Rectum B Lithium, Thyroxine No 8+
72 M Rectum B Captopril, Naproxen, Allopurinol, Isosorbide, Frusemide, Atenolol, Prochlorperazine No 1–7
78 M Colon A N/A No N/A
56 M Colon A None No 8+
76 M Colon A None No 1–7
44 M Colon C N/A No N/A
58 F Colon N/A None No 0
61 F Rectum A N/A No N/A
66 F Colon B None No 0
54 M Rectum C1 None No 1–7
49 M Colon B None No 8+
73 F Colon B N/A Yes N/A
52 M Rectum B None No 8+
68 M Colon B Salbutamol, Ferrous sulphate No 0
63 F Rectum A Salbutamol, Beclomethasone, Bendrofluazide No 1–7
56 M Colon C Losec No 8+
68 M Rectum B Sotalol, Aspirin No 8+
80 F Rectum B None No 0
59 M Rectum C1 None No 8+
66 M Rectum N/A None Yes 8+
N/A¼not available.
aAge in years.
bAlcohol consumption in units per week (1 unit¼half a pint of beer or one glass of wine or one shot of spirits).
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stissue was determined using a modified avidin–biotin immunohis-
tochemistry procedure (Goggi et al, 1986). In preliminary experi-
ments, each of the immunohistochemistry assays was optimised
using a range of antisera dilutions (1/50–1/5000). For each assay, the
negative control antisera (pre-immune sera) were confirmed
negative for staining at the dilution optimised for the primary
antibody and blocking peptides (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) confirmed specificity. The sections were
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sdeparaffinised and rehydrated through xylene and a series of graded
alcohol solutions. Endogenous peroxidase activity was blocked by
immersing the sections into a solution of 3% hydrogen peroxide in
distilled water for 30min at room temperature, and then rinsed in
cold running tap water for 10min. Incubating the sections with 5%
normal swine serum for 30min at room temperature reduced non-
specific background staining. Sections were then washed twice with
phosphate buffered saline (PBS) and 1ml of either the primary
antibody or the normal goat or rabbit IgGs (negative control) was
applied to each section, and left at 41C overnight. The next day, the
slides were washed twice with PBS, and then incubated with the
secondary antibody solution (Biotinylated swine anti-goat, mouse,
rabbit immunoglobulin; 1/150 dilution; 1ml per section), for 1h at
room temperature. After being washed twice with PBS, they were
incubated with the StrepABComplex solution (Dako Ltd, Ely, UK,
1ml per section) for 1h at room temperature, washed twice with PBS
and immersed into the substrate (300ml PBS, 90ml hydrogen
peroxide and 2.5ml 3,3-diaminobenzidine) for 3min, and then
rinsed with PBS and cold running tap water. Sections were then
successively immersed into haematoxylin, acid alcohol and Scott’s
tap water to counterstain. Finally, the sections were dehydrated by
successive immersion into 70% ethanol, 100% ethanol twice and
xylene twice and mounted.
Immunohistochemical evaluation
Processed specimens were scored under the light microscope
and the intensity and extent of staining with COX-2, NF-kB-p65,
NF-kB-p65 NLS, NF-kB-p50, NF-kB-p50 NLS and IKKa antibodies
graded blind using coded slides. To assess and grade intensity and
distribution of immunoreactivity in the colorectal stromal and
epithelial cells, a scoring method, which has been described earlier
was used (Yukawa et al, 1994). The distribution was scored
according to the number of positive cells; none (not stained), 0;
focal (o1/3 of cells stained), 1; multi-focal (1/3–2/3 of cells
stained), 2; and diffuse (42/3 stained), 3. The staining intensity
was scored as: none (not stained), 0; mild (between 0 and 2), 1; and
strong, 2. The distribution and intensity scored were added to
produce the following grades for the staining: 0, negative; 2, weakly
positive; and 3, 4 and 5, strongly positive. Sections treated with the
normal goat or rabbit IgGs (negative controls) or omitting the
primary antibody were devoid of staining. Positive staining
controls for COX-2 included sections of kidney, uterus and brain.
Statistical analysis
The Wilcoxon’s signed rank test was used to compare the scoring
of the respective immunoreactivity for COX-2, NF-kB-p65 and
IKKa between stromal cells of malignant and adjacent normal
tissues. The Pearson’s product-moment correlation coefficient test
was used to assess the relation between COX-2 expression and NF-
kB-p65 and IKKa, and in addition to assess correlation between
COX-2, NF-kB-p65 and IKKa and the Duke’s stages.
RESULTS
Expression of COX-2 in normal and malignant colorectal
tissue
Tissue sections of malignant and normal bowel from colorectal
cancer patients were investigated for COX-2 expression by
immunohistochemistry. Approximately, one-third of the patients
strongly expressed immunoreactive COX-2 (score X3) in
stromal cells of both normal and malignant colorectal tissue
(Figures 1 and 2A). Only 5 out of 23 patients strongly expressed
immunoreactive COX-2 in non-neoplastic epithelial cells. In
contrast, there was strong COX-2 expression in malignant
epithelial cells in more than half of the patients (17 out of 30
patients). The expression was cytoplasmic. Statistical analysis of
matched (normal vs malignant tissue from the same patient)
samples showed no significant difference in the respective
intensity scores of COX-2 of stromal cells in normal and malignant
tissues (Wilcoxon’s signed rank test; n¼23; P¼0.113 for
fibroblasts, P¼0.108 for macrophages, and P¼0.066 for VECs).
Cyclooxygenase-2 expression was significantly higher in malignant
epithelial cells when compared with adjacent normal epithelium
(Wilcoxon’s signed rank test; n¼23; P¼0.003).
Expression of NF-jB-p65 in normal and malignant
colorectal tissue
Tissue sections of normal and malignant bowel from colorectal
patients were also investigated for NF-kB-p65 expression. The
majority of colorectal cancer patients strongly expressed immuno-
reactive NF-kB-p65 (score X3) in macrophages and VECs of
normal colorectal tissue (Figures 1 and 2B). Moreover, about one-
third of patients strongly expressed immunoreactive NF-kB-p65
in normal fibroblasts, whereas only 3 out of 24 patients strongly
expressed immunoreactive NF-kB-p65 in normal epithelial cells. In
cancerous tissue, more than half of the samples showed strong
qNF-kB-p65 expression in malignant epithelial cells, whereas only
about a quarter to a third of the malignant tissues showed
significant NF-kB-p65 expression in stromal cells. In all cell types
of both normal and malignant tissue, the NF-kB-p65 staining was
both cytoplasmic and nuclear. Cytoplasmic NF-kB-p65 expression
represented both inactive protein, which is bound to IkB, as well as
Figure 1 Immunohistochemical localisation of COX-2, NF-kB-p65 and NF-kB-p65 NLS in normal and malignant colorectal tissue from the same patient.
The presence of the immunoreactive protein is indicated by brown staining. (A) Human malignant tissue treated with pre-immune sera as primary antibody
(negative control for COX-2) (magnification  10); (B) Human malignant tissue treated with anti-COX-2 antibody as primary antibody (positive control)
(magnification  10); (C) Epithelial cells, (D) VECs, (E) macrophages and (F) fibroblasts of normal colorectal tissue treated with anti-COX-2 primary
antibody (magnification  20 for epithelial cells,  10 for VECs and  40 for other two cell types); (G) Epithelial cells, (H) VECs, (I) macrophages and (J)
fibroblasts of malignant colorectal tissue treated with anti-COX-2 primary antibody (magnification  10 for epithelial cells,  30 for VECs and  50 for
other two cell types); (K) Tissue treated with pre-immune sera as primary antibody (negative control for NF-kB-p65) (magnification  10); (L) Tissue
treated with anti-NF-kB-p65 antibody as primary antibody (positive control) (magnification  10); (M) Epithelial cells, (N) VECs, (O) macrophages and (P)
fibroblasts of normal colorectal tissue treated with anti-NF-kB-p65 primary antibody (magnification  20 for epithelial cells and VECs,  40 for
macrophages and  30 for fibroblasts); (Q) Epithelial cells, (R) VECs, (S) macrophages and (T) fibroblasts of malignant colorectal tissue treated with anti-
NF-kB-p65 primary antibody (magnification  10 for epithelial cells,  20 for VECs and  40 for other two cell types). (U) Tissue treated with pre-immune
sera as primary antibody (negative control for NF-kB-p65 NLS) (magnification  10); (V) Tissue treated with anti-NF-kB-p65 NLS antibody as primary
antibody (positive control) (magnification  20); (W) Epithelial cells, (X) VECs, (Y) macrophages and (Z) fibroblasts of normal colorectal tissue treated
with anti-NF-kB-p65 NLS primary antibody (magnification  10 for epithelial cells and VECs, and  40 for macrophages and fibroblasts); (AA) Epithelial
cells, (AB) VECs, (AC) macrophages and (AD) fibroblasts of malignant colorectal tissue treated with anti-NF-kB-p65 NLS primary antibody (magnification
 10 for epithelial cells,  20 for VECs and  40 for other two cell types).
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sactive NF-kB-p65, which has been phosphorylated and released
from IkB, but which has still not translocated into the nucleus.
Nuclear NF-kB-p65 expression represented active protein. In order
to determine whether any of the cytoplasmic NF-kB-p65 protein
was in its active form, we investigated the NF-kB-p65 NLS
expression in six patients who expressed significant cytoplasmic
NF-kB-p65 (Figure 1). The anti-NF-kB-p65 NLS antibody speci-
fically recognises an epitope overlapping the NLS of the p65
subunit of the NF-kB heterodimer. This epitope is masked by I-kB
binding, and therefore the anti-NF-kB-p65 NLS antibody selec-
tively binds to I-kB free, activated form of NF-kB-p65 (Mitsiades
et al, 2006). In all cases, a significant proportion of the cytoplasmic
NF-kB-p65 was found to be in its active form. In addition, we also
confirmed that nuclear NF-kB-p65 represented active protein.
Statistical analysis of matched patient samples showed a significant
reduction in the respective intensity scores of NF-kB-p65 in
macrophages and VECs of malignant tissues compared with those
of normal adjacent colorectal tissue (Wilcoxon’s signed rank test;
n¼24; P¼0.027 for macrophages, and P¼0.032 for VECs). No
statistical difference was observed in similar analysis of fibroblasts
(Wilcoxon’s signed rank test; n¼24; P¼0.109). In contrast,
NF-kB-p65 expression was significantly higher in malignant
epithelial cells when compared with adjacent normal epithelium
(Wilcoxon’s signed rank test; n¼24; P¼0.004).
Expression of IKKa, and NF-jB-p50 in normal and
malignant colorectal tissue
There was little expression of immunoreactive IKKa in either
stromal or epithelial cells of normal colorectal tissues, indicating
that immunoreactive IKKa protein is not strongly expressed
constitutively in these cells (Figure 2C and 3). However, there was
a significant increase of IKKa expression in both stromal and
epithelial cells of malignant colorectal tissues. The staining was
purely cytoplasmic. Statistical analysis applied to matched patient
samples showed a significant increase in the respective intensity
scores of IKKa in both stromal and epithelial cells of malignant
tissue, compared with those of normal colorectal tissue (Wilcox-
on’s signed rank test; n¼18; P¼0.010 for macrophages, P¼0.006
for fibroblasts, P¼0.028 for VECs, and P¼0.005 for epithelial
cells). Tissue sections of normal and malignant bowel from
colorectal patients were also investigated for NF-kB-p50 expres-
sion (Figure 3). A similar expression pattern to that of IKKa was
observed for NF-kB-p50 in both normal and malignant tissue.
Most of the patients (7 out of 8) did not show any significant
NF-kB-p50 expression in either the stromal or epithelial cells of
normal tissue. However, there was a significant increase of NF-kB-
p50 expression in both stromal and epithelial cells of malignant
colorectal tissues. The staining was both cytoplasmic and nuclear.
Cytoplasmic NF-kB-p50 expression represented both inactive
protein, which is bound to IkB, as well as active NF-kB-p50,
which has been phosphorylated and released from IkB, but which
has still not translocated into the nucleus. Nuclear NF-kB-p50
expression represented active protein. In order to determine
whether any of the cytoplasmic NF-kB-p50 protein was in its
active form, we investigated the NF-kB-p50 NLS expression in six
patients who expressed significant cytoplasmic NF-kB-p50
(Figure 3). In all cases, only a small proportion of the cytoplasmic
NF-kB-p50 was found to be in its active form. As there was
available tissue from only eight patients to investigate the
expression of this protein, no statistical analysis was performed.
Co-expression of COX-2, NF-jB-p65, NF-jB-p50 and IKKa
in normal colorectal tissue
In order to determine whether there was co-expression of COX-2
and NF-kB-p65 or IKKa in normal colorectal tissue, serial
sections were examined for expression of the four proteins. In
the great majority of patients, strong (X3) COX-2 expression was
accompanied by both cytoplasmic and nuclear NF-kB-p65
expression in VECs (8 out of 9 patients) (Figure 4A). However,
only a proportion of patients who expressed strong COX-2 levels in
the other cell types within normal tissue, also expressed
immunoreactive NF-kB-p65 (4 out of 9 for fibroblasts; 5 out of 9
for macrophages; and 3 out of 5 for epithelial cells) (Figure 4A and B).
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Figure 2 Expression of COX-2 (A), NF-kB p65 (B) and IKKa (C)i n
matched normal and malignant colonic stromal and epithelial cells from 23
patients. *Significantly different (Pearson’s correlation test, Po0.03) from
normal tissue.
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sIn agreement with this histological finding, there was a significant
correlation between COX-2 expression and NF-kB-p65 expression
in VECs (Pearson’s correlation test, two-tailed, P¼0.011, n¼23),
but not in the other cell types (P¼0.192 for macrophages,
P¼0.171 for fibroblasts and P¼0.111 for epithelial cells) (Figure
4A and B). Cyclooxygenase-2 expression in normal tissue did not
correlate with either IKKa expression (Figure 4C and D) (1 out of
10 patients for macrophages; 1 out of 9 for VECs; 0 out of 11 for
fibroblasts; and 1 out of 4 for epithelial cells) or NF-kB-p50
expression (1 out of 5 patients for macrophages; 1 out of 4 for
VECs; 0 out of 5 for fibroblasts; and 1 out of 3 for epithelial cells).
In agreement with this histological finding, there was no
correlation between the expression of COX-2 and IKKa in stromal
cells of normal colorectal tissues (Pearson’s correlation test, two-
tailed, n¼23, P¼0.06 for macrophages, P¼0.709 for VECs, and
P¼0.222 for fibroblasts) (Figure 4C and D).
Co-expression of COX-2, NF-jB-p65, NF-jB-p50 and IKKa
in malignant colorectal tissue
Serial sections were also examined for co-expression of the four
proteins in malignant colorectal tissue (Figure 5). In the majority
of patients, COX-2 expression was accompanied by both
cytoplasmic and nuclear NF-kB-p65 expression in stromal cells
(Figure 4E and F) (11 out of 16 patients for macrophages; and 9 out
of 13 for VECs and fibroblasts). A total of 13 out of the 16 patients
who expressed COX-2 in malignant epithelial cells, expressed
NF-kB-p65 (Figure 4E). In agreement with this histological finding,
there was a significant correlation between COX-2 and NF-kB-p65
expression in all cell types (Pearson’s correlation test, two-tailed,
P¼0.019 for macrophages, P¼0.001 for VECs, P¼0.002 for
fibroblasts and P¼0.017 for epithelial cells) (Figure 4E and F).
Only a proportion of patients who expressed significant COX-2
levels in stromal cells of malignant tissues, also expressed
significant IKKa (Figure 4G and H) (3 out of 7 patients for
macrophages; 4 out of 7 for VECs; and 2 out of 6 for fibroblasts)
and NF-kB-p50 levels (3 out of 5 patients for macrophages; 3 out of
5 for VECs; and 2 out of 5 for fibroblasts). Statistically, there was
no correlation between COX-2 and IKKa in any of these cells in
malignant tissues (Pearson’s correlation test, two-tailed, P¼0.322
for macrophages, P¼0.378 for VECs, and P¼0.578 for fibroblasts)
(Figure 4G and H).
Association between COX-2, NF-jB-p65 or IKKa in stromal
cells and severity of colorectal cancer
Comparison of the expression of COX-2, NF-kB-p65 and IKKa in
stromal cells of both normal and malignant epithelium and
severity of colorectal cancer as determined by the Duke’s stage,
indicated that protein expression was not correlated with clinical
assessment of disease severity (Pearson’s correlation test, two-
tailed; n¼21 and P¼0.13 for COX-2 in normal macrophages;
n¼21 and P¼0.06 for COX-2 in normal VECs; n¼21 and
P¼0.12 for COX-2 in normal fibroblasts; n¼23 and P¼0.15 for
COX-2 in malignant macrophages; n¼23 and P¼0.20 for COX-2
in malignant VECs; n¼23 and P¼0.25 for COX-2 in malignant
fibroblasts; n¼21 and P¼0.34 for NF-kB-p65 in normal macro-
phages; n¼21 and P¼0.61 for NF-kB-p65 in normal VECs; n¼21
and P¼0.47 for NF-kB-p65 in normal fibroblasts; n¼24 and
P¼0.41 for NF-kB-p65 in malignant macrophages; n¼24 and
P¼0.46 for NF-kB-p65 in malignant VECs; n¼24 and P¼0.22 for
NF-kB-p65 in malignant fibroblasts; n¼15 and P¼0.07 for IKKa
in normal macrophages; n¼15 and P¼0.95 for IKKa in normal
VECs; n¼15 and P¼0.57 for IKKa in normal fibroblasts; n¼19
and P¼0.27 for IKKa in malignant macrophages; n¼19 and
P¼0.51 for IKKa in malignant VECs; n¼19 and P¼0.91 for IKKa
in malignant fibroblasts).
DISCUSSION
We found that both stromal and epithelial cells of malignant
colorectal tissue express COX-2, indicating that both could
contribute to the production of PGs within the tumour micro-
environment. These results are in agreement with earlier studies,
that found both stromal and epithelial colorectal cells expressing
COX-2 in colorectal adenomas (Arnoletti et al, 2005; Pisano et al,
2005; Tatsu et al, 2005) and carcinomas (Battu et al, 1998;
Yamashita et al, 2003; Ohta et al, 2006). We have reported earlier
(Charalambous et al, 2003), a significant increase of COX-2
expression in malignant colorectal epithelial cells, compared with
adjacent normal epithelium. We now report that this difference is
not observed in stromal cells. In fact, COX-2 expression was higher
in all three stromal cell types in normal colorectal tissue, compared
with malignant tissue, although the difference in expression was
not statistically significant. These results indicate that in malignant
tissue COX-2 expression is predominantly epithelial, whereas in
surrounding normal tissue it is predominantly stromal. This latter
observation is in agreement with earlier reports suggesting that
COX-2 expressed by stromal cells is directly involved in
angiogenesis, preparing the surrounding colorectal tissue for local
spread of malignant tumour (Williams et al, 2000; Sonoshita et al,
2002; Wendum et al, 2005).
Nuclear factor-kB is an inducible eukaryotic transcription
factor, which has a pivotal role in the regulation of the expression
of numerous genes involved in immune and inflammatory
responses (Sha, 1998; Bowie and O’Neil, 2000). In fact, NF-kBi s
not a single protein, but a small family of closely related protein
dimers, which bind to a common sequence motif known as the kB
site (Karin and Lin, 2002). Two regulatory pathways have been
described that control the activity of these proteins: the canonical
NF-kB pathway, which is normally triggered in response to
microbial and viral infections and exposure to pro-inflammatory
cytokines; and the alternative pathway, which is triggered by
certain members of the tumour necrosis factor (TNF) cytokine
family (Karin and Lin, 2002). Nuclear factor-kB-p65 is a member
of the canonical pathway, whereas NF-kB-p50 and IKKa are
members of the alternative pathway. Once in the nucleus, NF-kB
can regulate several genes, including COX-2.
We have shown earlier that upregulation of COX-2 is
accompanied by increased expression of NF-kB-p65 and
IKKa in malignant colorectal epithelial cells (Charalambous et al,
2003), supporting the proposal that NF-kB is involved in COX-2
induction in these cells. This was in agreement with earlier model
systems that showed expression of COX-2 was mediated by
NF-kB in human umbilical vein (Jones et al, 1993) and rheumatoid
synoviocytes (Crofford et al, 1997). Subsequent in vitro studies
provided further evidence in support of this hypothesis (Cherukuri
et al, 2005; Duque et al, 2006; Konson et al, 2006). In this
study, we have shown that NF-kB-p65 and, to a lesser extent, NF-
kB-p50 are not only upregulated in malignant epithelial cells, but
they are also significantly activated. Moreover, we have shown that
in stromal cells (macrophages, fibroblasts and VECs) of malignant
colorectal tissue, as well as in VECs of adjacent normal tissue,
COX-2 expression is closely correlated with NF-kB-p65, but
not with IKKa or NF-kB-p50. These results indicate that in these
cells, COX-2 induction may be mediated primarily through
activation of the canonical NF-kB pathway in preference to the
alternative pathway. These findings are in agreement with a recent
study, which showed that COX-2 expression in colorectal cancer
stromal cells, was associated with p-IkB-a, another member of the
NF-kB canonical pathway (Vandoros et al, 2006). Interestingly, in
normal tissue, COX-2 expression in macrophages and fibroblasts
was apparently not associated with either NF-kB-p65, IKKa or NF-
kB-p50.
In summary, we have shown that stromal cells of malignant
and surrounding normal colorectal tissue express COX-2. In all
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normal tissue, COX-2 expression was strongly associated with
NF-kB-p65 expression but not IKKa or NF-kB-p50, suggesting that
in these cells, COX-2 induction may be mediated primarily
through activation of the canonical NF-kB pathway. Finally,
the lack of association between COX-2, NF-kB-p65 or IKKa in
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sFigure 3 Immunohistochemical localisation of IKKa, NF-kB-p50 and NF-kB-p50 NLS in normal and malignant colorectal tissue from the same patient. The
presence of the immunoreactive protein is indicated by brown staining. (A) Human malignant tissue treated with pre-immune sera as primary antibody
(negative control for IKKa) (magnification  10); (B) Human malignant tissue treated with anti-IKKa antibody as primary antibody (positive control)
(magnification  10); (C) Epithelial cells, (D) VECs, (E) macrophages and (F) fibroblasts of normal colorectal tissue treated with anti-IKKa primary antibody
(magnification  20 for epithelial cells,  10 for VECs and  80 for other two cell types); (G) Epithelial cells, (H) VECs, (I) macrophages and (J) fibroblasts
of malignant colorectal tissue treated with anti-IKKa primary antibody (magnification  10 for epithelial cells,  20 for VECs and  80 for other two cell
types); (K) Tissue treated with pre-immune sera as primary antibody (negative control for NF-kB-p50) (magnification  10); (L) Tissue treated with anti-
NF-kB-p50 antibody as primary antibody (positive control) (magnification  10); (M) Epithelial cells, (N) VECs, (O) macrophages and (P) fibroblasts of
normal colorectal tissue treated with anti-NF-kB-p50 primary antibody (magnification  20 for epithelial cells and VECs,  40 for other two cell types); (Q)
Epithelial cells, (R) VECs, (S) macrophages and (T) fibroblasts of malignant colorectal tissue treated with anti-NF-kB-p50 primary antibody (magnification
 10 for epithelial cells and VECs,  40 for macrophages and  50 for fibroblasts). (U) Tissue treated with pre-immune sera as primary antibody (negative
control for NF-kB-p50 NLS) (magnification  10); (V) Tissue treated with anti-NF-kB-p50 NLS antibody as primary antibody (positive control)
(magnification  10); (W) Epithelial cells, (X) VECs, (Y) macrophages and (Z) fibroblasts of normal colorectal tissue treated with anti-NF-kB-p50 NLS
primary antibody (magnification  20 for epithelial cells,  10 for VECs and  40 for macrophages and fibroblasts); (AA) Epithelial cells, (AB) VECs, (AC)
macrophages and (AD) fibroblasts of malignant colorectal tissue treated with anti-NF-kB-p50 NLS primary antibody (magnification  20 for epithelial cells
and VECs,  30 for macrophages and  40 for fibroblasts).
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Figure 4 Expression of NF-kB and IKKa compared with COX-2 in normal (A–D) and malignant colonic tissues (E–H). Values are mean±s.e.m.
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cancer as determined by the Duke’s stage, suggests that
COX-2, NF-kB-p65 and IKKa expression are possibly early
post-initiation events, that could be involved in tumour
progression.
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